Fed. Circ. Revives Santarus' Suit Over Par's Generic Zegerid
The Federal Circuit on Tuesday partially revived Santarus Inc.'s bid to block Par Pharmaceutical Co.'s generic version of the heartburn drug Zegerid, reversing a lower court's ruling that claims of two...To view the full article, register now.
Already a subscriber? Click here to view full article